Fig. 2: Historical timeline of FDA-approved immunotherapies used in the treatment of brain metastases (BrMs) over the last 13 years.
From: Progress in personalized immunotherapy for patients with brain metastasis
The monoclonal antibodies (mAbs) are color-coded based on their targets: PD-1 mAbs are marked in yellow, PD-L1 in green, LAG-3 in red, and CTLA-4 inhibitors in blue.
